Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced today that HRS-8797 Tablets and...
Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of...
Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced today that the Phase...
China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
China Medical System Holdings Limited (CMS) (HKG: 0867) announced today that the National Medical Products...
Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced today that the US Food and Drug...
Novo Nordisk Secures EU Approval for Wegovy Pill, First Oral Semaglutide 25mg for Obesity Treatment
Novo Nordisk (NYSE: NVO) announced today that the European Commission (EC) has granted marketing authorization...
Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
Lepu Medical Technology (SHE: 300003) announced on July 15, 2026, that the National Medical Products...
Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug...
Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the...
WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
WuXi Biologics (HKG: 2269) announced on June 16, 2026, a comprehensive Contract Development, Research, and...
China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) issued the...
Johnson & Johnson Reports Q2 2026 Results with 6.6% Sales Growth, Raises Full-Year Guidance
Johnson & Johnson (J&J) (J&J, NYSE: JNJ) announced second-quarter 2026 results, reporting sales growth of...
Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics
Innovent Biologics (HKG: 1801) announced an exclusive license agreement with Spero Therapeutics, Inc. (NASDAQ: SPRO)...
Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger
Hansoh Pharmaceutical (HKG: 3692) announced a dual strategic transaction involving its portfolio company Avere Therapeutics,...
Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access
Everest Medicines (HKG: 1952) announced a strategic cooperation agreement with JD Healthcare (HKG: 6618) to...
Innovent Biologics Secures Macau Approval for Dual-Immunotherapy Neoadjuvant Regimen in MSI-H/dMMR Colon Cancer
Innovent Biologics (HKG: 1801) announced that its independently developed Daboxin (ipilimumab N01) has received marketing...
Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab...
CSPC Pharmaceutical Secures Dual NMPA Breakthrough Therapy Designations for HER2-Positive Breast Cancer Combination
CSPC Pharmaceutical Group (HKG: 1093) announced that its self-developed docetaxel (albumin-bound) (HB1801) and Anbenitamab (KN026)—developed...
Biogen Advances Diranersen into Phase 3 Development Following Positive Alzheimer’s Phase 2 Data
Biogen Inc. (NASDAQ: BIIB) presented positive Phase 2 CELIA study data for diranersen (BIIB080), an...
Sino Biopharmaceutical’s TRD205 Secures NMPA Breakthrough Therapy Designation for Chronic Post-Surgical Neuropathic Pain
Sino Biopharmaceutical (HKG: 1177) announced that TRD205, a Category 1 innovative drug self-developed by its...